Advertisement


Eileen M. O’Reilly, MD, on Pancreatic Adenocarcinoma: Gemcitabine, Cisplatin, and Veliparib

2020 Gastrointestinal Cancers Symposium

Advertisement

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II trial findings showing that cisplatin and gemcitabine, with or without veliparib, exceeded a prespecified response rate for patients with pancreatic adenocarcinoma and a germline BRCA/PALB2 mutation (Abstract 639).



Related Videos

Colorectal Cancer

Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool

Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cancer treated with mFOLFOX6. The study showed that patients with an intermediate or high Immunoscore seemed to benefit from 6 months of mFOLFOX6 treatment compared with 3 months (Abstract 10).

Colorectal Cancer
Immunotherapy

Thibaud Kössler, MD, PhD, on Localized Rectal Cancer: Neoadjuvant Pembrolizumab and Radiotherapy

Thibaud Kössler, MD, PhD, of Geneva University Hospital, discusses the first trial to study the efficacy and safety of anti–PD-1 immunotherapy plus short-course radiotherapy in localized microsatellite-stable rectal cancer. The study explores whether a gene signature can predict sensitivity to immunotherapy (Abstract TPS272).

Colorectal Cancer
Immunotherapy

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy

Heinz-Josef Lenz, MD, of USC Norris Comprehensive Cancer Center, discusses how treating microsatellite instability–high/DNA mismatch repair–deficient metastatic colorectal cancer with nivolumab once every 2 weeks plus low-dose ipilimumab every 6 weeks may represent a new option for patients (Abstract 11).

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Zev A. Wainberg, MD, on PD-L1­–Positive Advanced Gastric Cancer: MSI and Combined Positive Score and Pembrolizumab vs Chemotherapy

Zev A. Wainberg, MD, of the UCLA Medical Center, discusses the first subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in PD-L1–positive disease (Abstract 427).

Colorectal Cancer

Van K. Morris, MD, on Stage II Colon Cancer: Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy

Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses the COBRA study, which is examining circulating tumor DNA and its ability to predict whether patients with resected stage IIA colon cancer may benefit from adjuvant chemotherapy (Abstract TPS261).

Advertisement

Advertisement



Advertisement